Premium
Poor prognosis of mediastinal non‐Hodgkin's lymphoma with an immature phenotype of CD2+, CD7 (or CD5)+, CD3−, CD4−, and CD8−
Author(s) -
YumuraYagi Keiko,
Ishihara Shigehiko,
Hara Junichi,
Murata Mitsunori,
Izumi Yutaka,
Tawa Akio,
Sato Akiko,
Matsumoto Yoshio,
Kozaiwa Kosuke,
Nishida Masaru,
KawaHa Keisei
Publication year - 1989
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19890215)63:4<671::aid-cncr2820630413>3.0.co;2-x
Subject(s) - medicine , vincristine , cyclophosphamide , prednisolone , cd5 , lymphoma , gastroenterology , regimen , chemotherapy , non hodgkin's lymphoma , oncology
Nine children with mediastinal non‐Hodgkin's lymphoma (NHL) were treated according to our new regimen which is characterized by intensified therapy with high‐dose cytosine arabinoside (HDCA). After induction therapy with a combination of five drugs, such as vincristine, doxorubicin, cyclophosphamide, 1‐asparaginase, and prednisolone, intermediate dosages of methotrexate (MTX) (1 g/m 2 ) and HDCA (1.5 g/m 2 × 12 doses) were administered. All but one patient (88.9%) achieved complete remission and then received this intensified therapy. With a median follow‐up period of 25.5 months, five patients are still in complete remission, but three patients have relapsed. From the phenotypic point of view, these relapsed patients showed only very immature T‐cell differentiation antigens such as CD2 and CD7 (or CD5). These results suggest that HDCA as intensified therapy for children with mediastinal NHL seems to be effective. However, for patients with an immature phenotype of T‐lineage cells, more sophisticated regimens should be prepared.